Key result
Combining platelet function and HbA1c predicts early adverse events after PAD revascularisation with AUC ~0.89.
Why the study?
Does a dual-marker strategy integrating platelet function testing and glycaemic control predict early adverse outcomes in patients with PAD undergoing lower-limb revascularisation on clopidogrel monotherapy?
Does a dual-marker strategy integrating platelet function testing and glycaemic control predict early adverse outcomes in patients with PAD undergoing lower-limb revascularisation on clopidogrel monotherapy?
A dual-marker strategy combining platelet function testing and HbA1c accurately identifies PAD patients at high risk of early adverse outcomes following lower-limb revascularisation on clopidogrel monotherapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
MacDonald-Nethercott et al. (2026) studied this question. A dual-marker model combining platelet function and HbA1c accurately predicted early adverse events (AUC 0.89) in peripheral artery disease patients undergoing revascularisation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: